4DMedical COPD trial results presented at US lung conference

Latest News

Respiratory imaging technology company 4DMedical (ASX:4DX) has announced the presentation of findings of its chronic obstructive pulmonary disease (COPD) clinical trial undertaken at Johns Hopkins University Hospital in the US.

Investigators from Johns Hopkins and the University of Miami presented findings from their COPD study on Sunday 15 May at the International Conference of the American Thoracic Society.

The study involved 15 patients with a spectrum of COPD disease severity who received XV LVAS scans twice over the duration of the study. They also underwent other standard assessments of lung function, including Computed Tomography (CT) scans.

4DMedical said key findings included XV Technology derived metrics, specifically Ventilation Heterogeneity and Mean Specific Ventilation, correspond with COPD disease severity

In addition, XV Technology derived measures of regional lung function in COPD subjects showed reproducible results during repetitive examinations, pathophysiological insights were identified and have application in both clinical and research settings, and XV LVAS scans are capable of assessing regional ventilation defects, which is critical to the optimisation of treatment therapies.

The company said the study further demonstrated that XV Technology shows significant promise as a tool to phenotype or classify COPD disease.

4DMedical CEO and founder Dr Andreas Fouras said, “We are thrilled with the clinical trial results from the Johns Hopkins COPD study. The trial shows that XV Technology has significant promise as a tool to phenotype or classify COPD disease, which is critical for optimising treatment therapies.

"Clinical studies like this are a key pillar of our commercialisation strategy. We are excited that more of these studies are likely to conclude over the coming months, with results expected to be presented at key international conferences and published in medical journals. We are confident they will further validate the effectiveness of our unique medical technology offering and serve to make it easier to communicate with doctors and hospitals interested in our offering.”